ERDERA

European Rare Diseases Research Alliance

Basic Information

Description

The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in Rare Disease (RD) research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment. This Partnership will deliver a RD ecosystem that builds on the successes of previous programmes by supporting robust patient need-led research, developing new diagnostic methods and pathways, spearheading the digital transformational change connecting the dots between care, patient data and research, while ensuring strong alignment of strategies in RD research across countries and regions. Structuring goal-oriented public-private collaborations targeted at interventions all along the R&D value chain will ensure that the journey from knowledge to patient impact is expedited, thereby optimising EU innovation potential in RD. To support its ambition and missions ERDERA has been designed as a comprehensive and integrated ecosystem of which structure can be compared to an institute encompassing three main parts: (i) funding, (ii) internal (in house) Clinical Research Network that implements research activities targeting clinical trial readiness of RDs and accelerating diagnosis and translation of research discovery into improved patient care, and (iii) related supporting services (Data, Expertise, Education and Training) as well as an acceleration hub that serve external and internal RD community, all supported by all-embracing coordination and strategy and foundational (inter)national alignment.


H2020 Societal Challenges

HORIZON C1: Health


Research fields covered by the network

  • Health

Is connected with

Joint Calls

Joint Call Title Type Launch Date Deadline
Pre-Proposal
Deadline
Full-Proposal
Evaluation
End Date
Joint Transnational Call (JTC) 2025 "Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation" two-stages 10/12/2024 13/02/2025 09/07/2025 30/12/2025